Cantor Starts Helicos BioSciences (HLCS) at Buy; $14 PT
More News related to HLCS
- Helicos Launches Open Access Web Site With Microbial Genome Data
- Helicos BioSciences (HLCS) Reports Mixed Q3 Results
- Helicos BioSciences Reports Q3 2008 Financial Results
- Helicos BioSciences to Report Third Quarter 2008 Results on November 5, 2008
- Cantor Fitzgerald Downgrades Helicos BioSciences (HLCS) to Hold, But Sees Company as Potential Acquisition Target
More News related to New Coverage
- Citi Initiates Coverage on US Soft Drink Makers
- William Blair Initiates Coverage on Data Networking Stocks
- Caris Starts Coverage on Ariba (ARBA), Concur (CNQR), salesforce.com (CRM), Taleo (TLEO)
- Oppenheimer Initiates Coverage on ViroPharma (VPHM)
- Oppenheimer Initiates Coverage on Cadence Pharmaceuticals (CADX) with an Outperform
Cantor Fitzgerald initiates coverage on Helicos BioSciences Corp. (Nasdaq: HLCS) with a Buy rating and $14 price target.
The firm calls Helicos the likely market segment leader in the genome sequencing space due breakthroughs using the HeliScope system. Cantor believes "the HeliScope provides a quality and cost advantage that is unmatched in the current market" as the product is the first integrated, comprehensive system in this market.
Cantor notes that Helicos just shipped its first HeliScope unit during Q108 and the firm expects additional system installations to make the Company profitable by 2010.
Helicos BioSciences Corporation, a life sciences company, engages in the development of genetic analysis technologies for the research, drug discovery, and clinical diagnostics markets. [BCS]
Related Categories
New CoverageStocks Mentioned
-0.02Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
